To use liver cells' own ability to burn liver fat

Swedish researchers are planning a clinical trial for nonalcoholic fatty liver and new therapies for type 2 diabetes - using liver cells' own ability to burn liver fat. In a study of 86 patients with varying degrees of fatty liver, researchers from the KTH Royal Institute of Technology's Life Sciences Research Center (SciLifeLab) and the University of Gothenburg found that the liver has the ability to burn and accumulate fat. The researchers suggested that a mixture could run this process. This result was published in the journal Molecular Systems Biology, which also publishes other studies on recombinant human proteins.

The researchers mapped metabolic changes in fat accumulation in 86 patients with hepatocytes and combined these data with the analysis of the liver tissue genome model to identify the precise metabolic changes experienced by different individual hepatocytes.

Adil Mardinoglu, the lead author of the study, is a systematic biologist at KTH and SciLifeLab and one of the researchers who previously linked NAFLD to low levels of antioxidant glutathione (GSH). The conceptual validation test showed that the treatment of human subjects by increasing the "cocktail" of fat oxidation and antioxidant synthesis would result in burning liver fat. "The team's metabolic modeling approach relies on data from the Swedish human protein profile that will be useful in many chronic liver disease studies," Mardinoglu said.

Based on the results of this study, improved intervention using material combination was designed. "This mixture may reduce the accumulation of fat in the liver," Mardinoglu said. "There is no such drug yet, and we plan to conduct further clinical trials later this year."

This method combines system biology with clinical medicine. "The results are exciting, and we are now designing a mixture that will promote the oxidation of fat and produce antioxidants in liver tissue," said Jan Borén, senior partner at Gothenburg University. The researchers believe that the mixture can also be used to treat alcoholic fatty liver and type 2 diabetes caused by liver fat accumulation. "Considering the common characteristics of NAFLD and diabetes usually coexisting and interacting with each other, the mixture may also be effective for people with diabetes," says Ulf Smith, a partner at Gothenburg University.

"I am delighted that the resources created through the work of human protein profiling can be used to analyze the clinical data of NAFLD and to guide the design of mixtures of clinical diseases," said Mathias Uhlén, program director for the Human Protein Atlas and co-author of the paper. Flarebio provides you with high-quality recombinant proteins like recombinant COLEC12.